Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 41 Show results per page	View Search Criteria \| Help With Results


1.		Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Active				18 and over				Pharmaceutical / Industry				ECTCL1 NCT00221039


2.		Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				18 to 120				Pharmaceutical / Industry				CLBH589B2201 NCT00425555


3.		Study of Oral LBH589 in Adult Patients With Refractory/Resistant Cutaneous T-Cell Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				18 and over				Pharmaceutical / Industry				CLBH589B2212 NCT00490776


4.		Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Pharmaceutical / Industry				Hx-CD4-110 NCT00127881

Last Modified: 5/23/2007


5.		Phase I/II Study of Epstein Barr Virus Specific Cytotoxic T Lymphocytes from a Normal HLA-Compatible Donor in the Treatment of Patients With Epstein Barr Virus Associated Lymphomas and Other Lymphoproliferative Diseases

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				Not specified				Other				MSKCC-95024 NCI-V95-0685, NCT00002663

Last Modified: 6/7/2006 First Published: 10/1/2002


6.		Phase I/II Study of Alemtuzumab-Based Conditioning Followed By HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Advanced Mycosis Fungoides/Sezary Syndrome

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 to 70				NHLBI				NHLBI-02-H-0250 NCT00047060


7.		Ultraviolet (UVA and UVB) Light Therapy in the Treatment of Inflammatory Skin Conditions

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				10 to 80				Other				Derm 446 NCT00129415


8.		Phase I/II CPG 7909 + Local XRT in Recurrent Low-Grade Lymphomas

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				NCI, Other				LYMNHL0014 80057, LYMNHL0014, NCT00185965, NIH, NCT00185965

Last Modified: 5/2/2007 First Published: 8/18/2006


9.		Phase I/II Study of Gemcitabine Hydrochloride and Pemetrexed Disodium in Patients With Advanced Mycosis Fungoides or Sézary Syndrome

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				Over 18				NCI, Pharmaceutical / Industry				NU-05H8 NU-0310-101, LILLY-NU-05H8, NCT00369629

Last Modified: 9/29/2008 First Published: 2/26/2008


10.		Phase I/II Study of Reduced-Intensity Preparative Regimen Comprising Fludarabine, Busulfan, and Alemtuzumab Followed By Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematological Malignancies or Other Diseases

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				70 and under				Other				BCM-H-19386 BCM-FAB, H 19386, NCT00625144

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute